logo
logo
ETNB stock ticker logo

89bio, Inc.

NASDAQ•ETNB
CEO: Mr. Rohan Palekar
板块: Healthcare
行业: Biotechnology
上市日期: 2019-11-11
89bio, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapies for the treatment of liver and cardio-metabolic diseases. Its lead product candidate is pegozafermin, a glycoPEGylated analog of fibroblast growth factor 21 for the treatment of nonalcoholic steatohepatitis; and for the treatment of severe hypertriglyceridemia. The company was incorporated in 2018 and is headquartered in San Francisco, California.
联系方式
142 Sansome Street, Second Floor, San Francisco, CA, 94104, United States
415-432-9270
www.89bio.com
市值
$2.20B
市盈率 (TTM)
-7.8
24.5
股息率
--
52周最高
$15.06
52周最低
$4.16
52周范围
98%
排名70Top 99.2%
1.1
F-Score
改良版 Piotroski 分析
基于 7 年期基本面
疲弱 • 1.1 / 9 分
评分区间 (0-9)
8-9: 价值优异
6-7: 基本面强劲
4-5: 整体稳健
0-3: 表现疲弱
数据范围: 2019-2025

深度研究

财务数据
电话会议
财务报告
新闻
利润表
资产负债表
现金流量表
财务比率
变化率
利润表
过去12个月
无数据